NEW YORK, NY / ACCESSWIRE / July 19, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Masimo Corporation ("Masimo" or "the Company") (NASDAQ:MASI). Investors who purchased Masimo securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/masi.
The investigation concerns whether Masimo has violated federal securities laws.
Investigation Details:
On July 17, 2023, Masimo issued a press release announcing its preliminary revenue results for the second quarter of 2023. Masimo advised that it anticipates revenue of between $453 million and $457 million for the quarter, significantly less than the $540.87 million consensus estimate. Masimo attributed the lower-than-expected revenue to a drop in healthcare revenue caused by delays in large orders, falling single-patient use sensor sales, lower customer conversions and decreasing demand for its products from hospitals. On this news, Masimo's stock price fell sharply during intraday trading on July 18, 2023.
What's Next?
If you are aware of any facts relating to this investigation or purchasedMasimo securities, you can assist this investigation by visiting the firm's site: www.bgandg.com/masi. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC